JPM19: A biotech's M&A invitation, Editas' next CRISPR step and more from day 3

JPM19: A biotech's M&A invitation, Editas' next CRISPR step and more from day 3

Source: 
Biopharma Dive
snippet: 

Pharma can't have an $8 billion deal every day. That was evident Wednesday, as the buzz within the Westin St. Francis tapered off for the first time since the 37th annual J.P. Morgan Healthcare Conference began.